PDCD1 and neoplasm: Independently, a recently published study on the animal model showed that tumor-infiltrating MCs are associated with resistance to anti-PD-1 therapy, and combining anti-PD-1 with sunitinib/imatinib results in depletion of mast cells, leading to complete regression of melanoma [50].